Sotorasib (AMG510), a selective and irreversible small-molecule suppressor targeting the KRAS G12C mutation, has shown promising antitumor effects in non-small-cell lung cancer (NSCLC) (46), as well as other solid tumors, especially pancreatic cancers with the KRAS G12C mutation (47). This evidence concerns the gene KRAS and non-small cell lung carcinoma.